It's an Exciting Time for Myelodysplastic Syndrome

Trust me, I made the mistake of blaming every symptom on my cancer.

Reblozyl for anemia in patients with an MDS subset demonstrated positive effects, compared with previous treatments, according to an MDS expert.

Hematopoietic cell transplantation improved survival among high-risk genetic subgroups of patients with myelodysplastic syndrome, a recent study found.

As The Los Angeles Rams celebrate a cancer survivor and a 9/11 survivor reveals his fourth cancer diagnosis, this is what’s happening in the oncology space this week.

Here’s a look back at blood cancer approvals from the summer of 2023.

The Food and Drug Administration approved Reblozyl to treat low red blood cell count in patients with very low- to intermediate-risk myelodysplastic syndrome.